Extreme caution warranted. The company's micro-revenue ($38,789/yr) cannot support its escalating cash burn ($7.1M/yr). This deeply discounted offering (53-68% below market) at only $8M market cap suggests desperate capital needs. Monitor for post-offering cash runway disclosure and any news on SFDA/NMPA approvals or FDA clearance monetization. The 6-month lock-up on existing holders provides temporary float protection, but dilution risk is acute.
Executive Summary
Cuprina Holdings filed Amendment No. 1 to its F-1 registration statement for a follow-on public offering of 4,322,489 Class A ordinary shares, with the offering price estimated between $1.00 and $1.50 per share — a deep discount to the $3.16 closing price on September 4, 2026. The Singapore-based chronic wound care and cosmeceutical company generated just US$38,789 in revenue in FY2025 (up 3.3% YoY) while recording a net loss of US$3.6M and an accumulated deficit of US$7.2M. The offering is heavily dilutive (4.7x existing Class A shares outstanding) and proceeds of ~US$3.74M are primarily earmarked for expansion into new businesses and R&D, but the company's micro-revenue base and history of steep operating cash burn ($7.1M in FY2025) raise serious sustainability concerns.
Key Financial Metrics
Key Facts
- Public offering of 4,322,489 Class A ordinary shares (plus 648,373 over-allotment option) at an estimated price range of $1.00–$1.50 per share — a 53-68% discount to the $3.16 closing price on Sept 4, 2026
- Net proceeds expected to be ~US$3.74M (or ~US$4.33M if over-allotment exercised in full)
- FY2025 revenue of US$38,789 (up 3.3% YoY from S$48,321 to S$49,894) but net loss of US$3.6M (S$4,673,447) and accumulated deficit of US$7.2M (S$9,234,500)
- Operating cash outflow of US$7.1M (S$9,133,948) in FY2025 vs. US$0.96M (S$1,235,981) in FY2024 — burn rate accelerated 7.4x
- IPO completed April 2025; this is the second F-1 amendment (first was July 2026); 10 offering/registration filings in last 24 months
- Company has 10 full-time employees, 2 R&D staff; generates 88.6% of revenue from MEDIFLY maggot debridement products, which have no patent protection
- Additional shares: 648,373 over-allotment shares and up to 198,835 shares underlying Representative's Warrants at 110% of offering price
Financial Impact
Dilution of ~469% to existing Class A shareholders (from 920,644 to 5,243,133 Class A shares), raising ~US$3.74M net — but the company burned US$7.1M in operating cash in FY2025 alone, indicating the raise barely covers 6 months of cash burn
Risk Factors
- Micro-revenue business raising capital at 53-68% discount to market price signals financial distress
- Operating cash burn of $7.1M in FY2025 far exceeds the ~$3.74M net proceeds — company will need additional capital within months
- No patent protection on core MEDIFLY product (88.6% of revenue); competitors could launch substantially equivalent products
- History of losses with no near-term path to profitability; accumulated deficit of $7.2M against $8M market cap
- Material weakness in internal controls (no written customer contracts; orders via WhatsApp) identified
- Highly dilutive offering — 4.7x existing Class A shares, with additional potential dilution from warrants and over-allotment
- Dual-class voting structure concentrates 97.1% voting power with pre-offering holders, limiting minority shareholder influence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (CUPR) — Batch item 1 | 0001493152-26-042322 |
| Exhibit: ex5-1.htm | 0001493152-26-042322 |
| Exhibit: ex107.htm | 0001493152-26-042322 |
| Exhibit: ex99-7.htm | 0001493152-26-042322 |
| Exhibit: ex23-1.htm | 0001493152-26-042322 |
| Exhibit: ex23-2.htm | 0001493152-26-042322 |
| Document: 0001493152-26-042322-index-headers.html | 0001493152-26-042322 |
| Document: 0001493152-26-042322-index.html | 0001493152-26-042322 |
| Document: 0001493152-26-042322.txt | 0001493152-26-042322 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $1.93 $1.85 | ▲ +4.15% | ▲ +4.22% | $1.80 (+6.74%) |
Oct 2, 2026 25d ago | 6-K | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.80 (−25.62%) |
Oct 2, 2026 25d ago | Press Release | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.80 (−25.62%) |
Sep 29, 2026 28d ago | 6-K | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.80 (+21.05%) |
Sep 29, 2026 28d ago | Press Release | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.80 (+21.05%) |
Sep 18, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.80 (−0.56%) |
Sep 17, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.80 (−0.56%) |
Sep 17, 2026 5w ago | Press Release | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.80 (−0.56%) |
Sep 16, 2026 5w ago | 424B4 | $1.60 $1.88 | ▼ −17.50% | ▼ −15.68% | $1.80 (−12.50%) |
Sep 16, 2026 5w ago | EFFECT | $1.60 $1.88 | ▼ −17.50% | ▼ −14.94% | $1.80 (−12.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers